Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
regulators
Biotech
Ipsen still out of luck as EC rejects rare disease drug
While Ipsen’s troubled rare disease candidate was given a second chance by the FDA, the regulator’s European equivalents haven’t been as sympathetic.
James Waldron
Jul 20, 2023 6:32am
Biogen pays Roche $30M as lymphoma bispecific heads to FDA, EU
Feb 1, 2022 11:00am
EMA sets out plan to accelerate clinical trials
Jan 14, 2022 7:15am
Biden and biotech: Science first
Jan 20, 2021 9:00am
Staff resist executive order amid fears Trump could reshape FDA
Nov 3, 2020 9:45am
FDA de novo pathway clearing devices without enough evidence
Oct 23, 2020 9:15am
